ad image

Company Info

DNAtrix

DNAtrix

Drug Discovery & Development

Overview

DNAtrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. Its oncolytic adenovirus platform viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors.  DNAtrix has multiple virus candidates in clinical trials for cancers with urgent needs for novel approaches. 
0 Contributors1 / 0

No authors found

1 / 0